Company Overview and News
BOULEVARD Holdings, Inc. (BHI) saw a significant drop in sales of products and services for the month of May, following the six-month closure of Boracay Island where the company operates a beach resort.
Boulevard Holdings, Inc. (BHI) saw a significant drop in sales of products and services for the month of May, following the six-month closure of Boracay Island where the company operates a beach resort.
REVOLUTION Precrafted Properties Philippines, Inc. has been tapped by Boulevard Holdings, Inc. (BHI) for an integrated resort project in Cavite that is expected to generate P6 billion in sales.
2018-04-25 bworldonline - 1
Boulevard Holdings, Inc. (BHI) has provided countermeasures for the company’s operations in Boracay given the island’s shutdown on Thursday, April 26, including the payment of P7,000 per month to its regular employees until Boracay’s reopening.
BUSINESSES continue to navigate through the haze of uncertainty in the aftermath of the government’s decision to close the island of Boracay for rehabilitation.
0027 BHI GXYEF GXYYY
The operator of Fridays Boracay Beach Resort will take a hit following the “impulsive” decision of the government to close the island for rehabilitation, prompting Boulevard Holdings, Inc. (BHI) to ramp up the sales of its property in Puerto Galera.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to PSE:BHI / Boulevard Holdings, Inc. on message board site Silicon Investor.